Literature DB >> 32069388

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China.

Sebastian Hoehl1, Holger Rabenau1, Annemarie Berger1, Marhild Kortenbusch1, Jindrich Cinatl1, Denisa Bojkova1, Pia Behrens2, Boris Böddinghaus2, Udo Götsch2, Frank Naujoks2, Peter Neumann2, Joscha Schork2, Petra Tiarks-Jungk2, Antoni Walczok2, Markus Eickmann3, Maria J G T Vehreschild1, Gerrit Kann1, Timo Wolf1, René Gottschalk2, Sandra Ciesek4.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32069388      PMCID: PMC7121749          DOI: 10.1056/NEJMc2001899

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
To the Editor: As the number of cases of infection with the novel coronavirus (SARS-CoV-2) has continued to increase, many countries have established restrictions regarding travelers who have recently visited China.[1] With lockdown measures imposed in Hubei Province, China,[2] and a public health emergency of international concern declared by the World Health Organization,[3] foreign nationals have sought to return to their home countries from China, and public health authorities are racing to contain the spread of Covid-19 (the disease caused by SARS-CoV-2 infection) around the world. This process is complicated by epidemiologic uncertainty regarding possible transmission of the virus by asymptomatically or subclinically symptomatic infected persons. It is unclear whether persons who show no signs or symptoms of respiratory infection shed SARS-CoV-2. In this context, a group of predominantly German nationals who had stayed in Hubei Province was evacuated to Frankfurt, Germany, on February 1, 2020. They were to be transferred to Germersheim, Germany, and quarantined for 14 days, since this period is thought to be the upper limit of the incubation period of SARS-CoV-2. Screening for symptoms and clinical signs of infection was performed before their departure from China. A total of 126 travelers were allowed to board an aircraft operated by the German air force (Figure 1).
Figure 1

Evaluation and Testing of Passengers.

Passengers were evaluated to detect infection with the novel coronavirus (SARS-CoV-2) after their flight from Wuhan, China, to Frankfurt, Germany. All tests were targeted to detect SARS-CoV-2.

During the flight, 10 passengers were isolated. Two passengers had had contact with 1 person who had a confirmed case of SARS-CoV-2 infection, 6 had reported symptoms, were deemed to be clinically symptomatic, or both, and 2 passengers had accompanied family members who had been isolated on the flight because of suspected SARS-CoV-2 infection or because of other symptoms (i.e., symptoms related to pregnancy). These 10 passengers were transferred to University Hospital Frankfurt immediately after arrival. All 10 tested negative for SARS-CoV-2 by real-time reverse-transcription–polymerase-chain-reaction (RT-PCR) assays[4] of throat swabs and sputum. The remaining 116 passengers (5 months to 68 years of age), including 23 children, were sent to the medical assessment center at Frankfurt Airport, where each was evaluated by a medical team of physicians. Each passenger was asked to report current symptoms of fever, fatigue, sore throat, cough, runny nose, muscle aches, and diarrhea, and each one was screened for signs of infection in the nose and throat. The temperature of all passengers was taken. All were afebrile except for 1 passenger who had a temperature of 38.4°C and reported dyspnea and cough. He was transferred to University Hospital Frankfurt for evaluation. However, testing to detect SARS-CoV-2 by RT-PCR of a throat swab and sputum was negative. In addition to the preplanned multistep process of screening for signs and symptoms of infection and observing the asymptomatic cohort in quarantine, we decided to offer a throat swab to test for SARS-CoV-2 in each of the 115 travelers who had passed triage. A total of 114 passengers consented to the test. Two of the 114 persons (1.8%) in this cohort of travelers who had passed the symptoms-based screening tested positive for SARS-CoV-2 by RT-PCR (cycle threshold value in the two samples, 24.39 and 30.25, respectively). Testing with a second protocol consisting of two commercial sets (LightMix Modular SARS and Wuhan CoV E-gene, and LightMix Modular Wuhan CoV RdRP-gene, both produced by TIB MOLBIOL) and retesting of the positive samples at the Institute of Virology, Philipps University Marburg, in Marburg, Germany, confirmed the results. In addition, the isolation of SARS-CoV-2 from both samples in cell culture of Caco-2 cells indicated potential infectivity (see the Supplementary Appendix, available with the full text of this letter at NEJM.org). These two persons were subsequently isolated from the cohort and transferred to the Infectious Disease Unit at University Hospital Frankfurt for further evaluation and observation on the following day. After a thorough evaluation in the hospital ward, a faint rash and minimal pharyngitis were observed in one patient. Both patients remained well and afebrile 7 days after admission. In this effort to evacuate 126 people from Wuhan to Frankfurt, a symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later were found to have evidence of SARS-CoV-2 in a throat swab. We discovered that shedding of potentially infectious virus may occur in persons who have no fever and no signs or only minor signs of infection.
  1 in total

1.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01
  1 in total
  215 in total

1.  Unmasking the mask: the role of personal protective equipment for ophthalmologists caring for asymptomatic patients during the COVID-19 pandemic.

Authors:  Adrian T Fung
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

2.  Emergency department response to COVID-19 outbreak with a fever screening station and "graded approach" for isolation and testing.

Authors:  Julia Chia-Yu Chang; You-Hsu Chen; Meng-Chen Lin; Yi-Jing Li; Teh-Fu Hsu; Hsien-Hao Huang; David Hung-Tsang Yen
Journal:  J Chin Med Assoc       Date:  2020-09-02       Impact factor: 2.743

3.  COVID-19 - Implications on and of Surgical Practices: Where Do We Draw the Line?

Authors:  Nishant Ganesh Kumar; Brian C Drolet
Journal:  Ann Surg       Date:  2020-05-01       Impact factor: 12.969

4.  SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine.

Authors:  Kayoko Hayakawa; Satoshi Kutsuna; Takeo Kawamata; Yuko Sugiki; Chiharu Nonaka; Keiko Tanaka; Michi Shoji; Masaki Nagai; Shunsuke Tezuka; Kazuyuki Shinya; Hiroki Saito; Takahiro Harada; Nin Moriya; Motoyuki Tsuboi; Masataro Norizuki; Yasuo Sugiura; Yasuyo Osanai; Masaya Sugiyama; Ayako Okuhama; Kohei Kanda; Yuji Wakimoto; Mugen Ujiie; Shinichiro Morioka; Kei Yamamoto; Noriko Kinoshita; Masahiro Ishikane; Sho Saito; Yuki Moriyama; Masayuki Ota; Keiji Nakamura; Takato Nakamoto; Satoshi Ide; Hidetoshi Nomoto; Yutaro Akiyama; Tetsuya Suzuki; Yusuke Miyazato; Yoshiaki Gu; Nobuaki Matsunaga; Shinya Tsuzuki; Yumiko Fujitomo; Yoshiki Kusama; Hiroyuki Shichino; Masao Kaneshige; Junko Yamanaka; Miki Saito; Masayuki Hojo; Masao Hashimoto; Shinyu Izumi; Jin Takasaki; Manabu Suzuki; Keita Sakamoto; Yukio Hiroi; Sakurako Emoto; Makoto Tokuhara; Toshiaki Kobayashi; Koichiro Tomiyama; Fumihiko Nakamura; Norio Ohmagari; Haruhito Sugiyama
Journal:  Glob Health Med       Date:  2020-04-30

5.  Neutralization Assay for SARS-CoV-2 Infection: Plaque Reduction Neutralization Test.

Authors:  Sandra Westhaus; Holger F Rabenau
Journal:  Methods Mol Biol       Date:  2022

6.  Is the New Coronavirus Disease (COVID-19) Pandemic Halted by Malaria Epidemics?

Authors:  Reza Hajizadeh; Mahsa Behnemoon
Journal:  Arch Bone Jt Surg       Date:  2020-04

7.  Single-cell landscape of immunological responses in patients with COVID-19.

Authors:  Ji-Yuan Zhang; Xiang-Ming Wang; Xudong Xing; Zhe Xu; Chao Zhang; Jin-Wen Song; Xing Fan; Peng Xia; Jun-Liang Fu; Si-Yu Wang; Ruo-Nan Xu; Xiao-Peng Dai; Lei Shi; Lei Huang; Tian-Jun Jiang; Ming Shi; Yuxia Zhang; Alimuddin Zumla; Markus Maeurer; Fan Bai; Fu-Sheng Wang
Journal:  Nat Immunol       Date:  2020-08-12       Impact factor: 25.606

8.  Seroprevalence of SARS-CoV-2 Antibody in Echocardiography and Stress Laboratory.

Authors:  Renuka Jain; Stacie Kroboth; Denise Ignatowski; Bijoy K Khandheria
Journal:  J Patient Cent Res Rev       Date:  2021-04-19

9.  Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management.

Authors:  Reza Fekrazad; Sohrab Asefi; Maryam Pourhajibagher; Farshid Vahdatinia; Sepehr Fekrazad; Abbas Bahador; Heidi Abrahamse; Michael R Hamblin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.

Authors:  Jimin Xu; Yu Xue; Richard Zhou; Pei-Yong Shi; Hongmin Li; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-05       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.